证券记录 · 已归档季度
CYTK
Cytokinetics, Incorporated · Healthcare · Biotechnology
19被追踪持有人
+2Δ持有人
69.14M持有股份
$3.80B报告持仓市值
+2新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 +11.8% ·
股份流向 +3.0% ·
净新建仓位 +5.3%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 128 | +7 | 95.72M | $8.15B | +10 | −2 |
| Q1 2026 | 123 | +1 | 87.96M | $5.79B | +8 | −8 |
| Q4 2025 | 121 | -1 | 92.45M | $5.87B | +2 | −2 |
| Q3 2025 | 19 | +2 | 69.14M | $3.80B | +2 | −1 |
| Q2 2025 | 15 | -2 | 62.06M | $2.05B | — | −2 |
| Q1 2025 | 14 | +1 | 26.36M | $1.06B | +1 | — |
| Q4 2024 | 13 | -1 | 25.19M | $1.18B | — | −1 |
| Q3 2024 | 13 | +2 | 19.21M | $1.01B | +2 | — |
| Q2 2024 | 11 | — | 17.42M | $943.61M | — | — |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 15.53M | -1.0% | $853.30M | 0.0% | ▼ Trim | 2 | SEC ↗ ×17 |
| 2 | Fidelity (FMR) ✦ | 13.09M | +16.2% | $719.52M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | The Vanguard Group ✦ (被动) | 11.86M | -1.1% | $651.65M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 4 | Wellington Management ✦ | 7.41M | -5.3% | $407.17M | 0.1% | ▼ Trim | 6 | SEC ↗ ×8 |
| 5 | State Street Global Advisors ✦ (被动) | 5.62M | -11.8% | $308.73M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | JPMorgan Chase ✦ | 3.09M | — | $169.59M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 7 | Geode Capital Management ✦ (被动) | 3.04M | +1.5% | $167.11M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 2.37M | +26.8% | $130.08M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Goldman Sachs Group ✦ | 1.63M | — | $89.84M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 10 | Morgan Stanley ✦ | 1.52M | — | $83.60M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 11 | Citadel Advisors ✦ | 1.39M | +6.7% | $76.18M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 12 | Fisher Asset Management ✦ | 761.59K | +3.8% | $41.86M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 513.29K | +47.6% | $28.21M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 14 | Point72 Asset Management ✦ | 471.48K | 新增 | $25.91M | 0.1% | New | 1 | SEC ↗ |
| 15 | Millennium Management ✦ | 342.53K | -25.3% | $18.83M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 289.97K | +2752.0% | $15.94M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | Marshall Wace ✦ | 178.98K | +743.2% | $9.84M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 18 | Adage Capital Partners ✦ | 38.00K | 新增 | $2.09M | 0.0% | New | 1 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 13.60K | -28.7% | $747,621 | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Point72 Asset Management | $25.91M | 0.1% |
| Adage Capital Partners | $2.09M | 0.0% |
已清仓
| Norges Bank | $39.12M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 437 持有人, 145.17M 股份, $8.22B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 06
Malik Fady Ibraham
Officer · 3.50K 股 · $214,830
Sep 28
Blum Robert I
Officer, Director · 7.50K 股 · $490,950
Sep 22
Malik Fady Ibraham
Officer · 3.50K 股 · $239,015
Sep 15
Landry Robert E
Director · 1.00K 股 · $72,130
Sep 15
Blum Robert I
Officer, Director · 97.93K 股 · $6.79M
Sep 14
Blum Robert I
Officer, Director · 7.50K 股 · $550,800
Sep 11
Landry Robert E
Director · 1.00K 股 · $74,660
Sep 08
Malik Fady Ibraham
Officer · 3.50K 股 · $264,110
Sep 01
PARSHALL B LYNNE
Director · 5.00K 股 · $357,400
Aug 31
Callos Andrew
Officer · 10.00K 股 · $702,400
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 13
SC 13G/A — WELLINGTON MANAGEMENT GROUP LLP
Jul 08
SC 13G/A — FMR LLC
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据